Leerink Partnrs Issues Optimistic Estimate for TVTX Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Stock analysts at Leerink Partnrs upped their FY2026 earnings per share estimates for shares of Travere Therapeutics in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now expects that the company will earn $0.52 per share for the year, up from their previous forecast of $0.51. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.93) per share.

TVTX has been the subject of a number of other reports. Guggenheim lifted their price target on shares of Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Leerink Partners reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Travere Therapeutics in a research note on Tuesday, October 8th. Wells Fargo & Company raised Travere Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $9.00 to $27.00 in a research report on Monday, October 21st. Scotiabank upped their target price on shares of Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. Finally, Canaccord Genuity Group dropped their price target on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, September 30th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Travere Therapeutics Price Performance

Shares of Travere Therapeutics stock opened at $18.37 on Tuesday. The firm’s 50-day moving average price is $18.20 and its 200 day moving average price is $14.63. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $20.33. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm had revenue of $62.90 million during the quarter, compared to analyst estimates of $60.87 million. During the same period in the previous year, the firm earned ($1.17) EPS. The business’s quarterly revenue was up 69.6% on a year-over-year basis.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, insider Jula Inrig sold 2,066 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $19.10, for a total value of $39,460.60. Following the sale, the insider now owns 59,883 shares in the company, valued at approximately $1,143,765.30. This trade represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Sandra Calvin sold 15,000 shares of the firm’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00. Following the transaction, the chief accounting officer now directly owns 54,927 shares in the company, valued at approximately $945,842.94. The trade was a 21.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 29,596 shares of company stock valued at $527,262 over the last three months. 4.06% of the stock is owned by company insiders.

Institutional Investors Weigh In On Travere Therapeutics

Several large investors have recently made changes to their positions in TVTX. Millennium Management LLC lifted its holdings in shares of Travere Therapeutics by 33.9% during the 2nd quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after acquiring an additional 747,406 shares during the period. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of Travere Therapeutics by 203.0% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 615,000 shares of the company’s stock valued at $5,055,000 after purchasing an additional 412,000 shares during the period. Emerald Advisers LLC raised its holdings in shares of Travere Therapeutics by 19.8% in the 3rd quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock worth $27,430,000 after buying an additional 323,513 shares in the last quarter. Emerald Mutual Fund Advisers Trust lifted its position in shares of Travere Therapeutics by 26.0% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock worth $16,588,000 after buying an additional 244,444 shares during the period. Finally, Walleye Capital LLC boosted its stake in Travere Therapeutics by 70.1% in the 3rd quarter. Walleye Capital LLC now owns 488,453 shares of the company’s stock valued at $6,833,000 after buying an additional 201,282 shares in the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.